🔗 Share this article

As America continues making historic changes to its immunization schedules, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by casting doubt on COVID-19 shots throughout the pandemic and has focused upon alleged fatalities after COVID-19 vaccination in her short time at the Food and Drug Administration.

Proposed Shifts to Pediatric Immunization Schedule

Health officials were set to unveil radical revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish national calendar, it is understood – a major change that would place the US out of alignment with much of the world with insufficient data for benefit. The planned update has been pushed back until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to head the center this calendar year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific childhood shot schedules in the US so as to align more in line with Denmark, a country with nationalized medicine and a population roughly the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccines – usually the purview of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Qualifications

Høeg has no apparent experience in medication creation, oversight or administrative roles, which has been customary for previous directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the CDER, stated Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She has no expertise in industry regulation.”

Previous heads of CBER would “be deeply familiar with laws and regulations and the science of medication creation”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that former directors who headed CBER have had.”

This division has an enormous range of responsibilities at the FDA, Woodcock stated.

“Everybody just zeroes in on the innovative therapies, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and each of these need to be managed,” she explained. “The responsibility you overlook, that is the part that I always told people is going to bite you.”

Additionally, a major leadership aspect to the position, which oversees in excess of 5,000 personnel. “It is a huge leadership role, if you do it right,” Woodcock added.

Official Statement and Controversial Policies

Regarding inquiries about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among agency officials on vaccines, a spokesperson said that the “inquiries are based on incorrect presumptions”.

“This background is consistent with the duties of her role,” the spokesperson explained, citing the period Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a controversial one-day therapy clearance system that apparently troubled her predecessors. “By what process are these medications being picked for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he said, “the FDA seems to be moving towards laxer regulations of most medications, with the exception of vaccines.”

Documented Track Record on Immunizations

With immunizations, Høeg has a clearer, if concerning, history, critics said. She published a research paper using non-validated crowd-sourced reports to assess the frequency of myocarditis following COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccinations are riskier than they are.

Part of her “wish list” for the new administration included changing rules for novel immunizations and halting “optional” vaccines, she remarked after the election on a podcast. At the agency, Høeg has reportedly proposed barring adolescent males from receiving Covid vaccinations.

“She is an complete true believer who begins with her beliefs and reverse-engineers to retrofit the evidence in a highly disingenuous, fraudulent way,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|